Related Experiment Videos
[Experimental and clinical studies on cefoperazone (author's transl)]
The Japanese Journal of Antibiotics
|August 1, 1980
Summary
Cefoperazone (CPZ) demonstrates potent antibacterial activity against Gram-positive and Gram-negative bacteria, including S. aureus and P. aeruginosa. Clinical studies show a 90.3% efficacy rate in treating various infections, with favorable pharmacokinetics.
Area of Science:
- Pharmacology
- Microbiology
- Clinical Medicine
Background:
- A novel synthetic cephalosporin antibiotic, cefoperazone (CPZ), was evaluated for its antibacterial properties and clinical efficacy.
- Comparative analysis included established antibiotics like cefazolin (CEZ), cephalothin (CET), gentamicin (GM), and cefotaxime (CTX).
Observation:
- CPZ exhibited significant activity against Staphylococcus aureus, with a low minimum inhibitory concentration (MIC).
- It demonstrated potent activity against Gram-negative bacteria, including Escherichia coli, Klebsiella sp., Proteus sp., and notably Pseudomonas aeruginosa, outperforming CTX.
- Pharmacokinetic studies showed favorable blood concentration peaks and half-lives following intravenous administration and infusion.
Findings:
- CPZ achieved a 90.3% efficacy rate in 31 clinical cases, including respiratory tract infections, urinary tract infections, and meningitis.
- Effective concentrations were observed in cerebrospinal fluid, indicating potential for central nervous system infections.
- Minor side effects such as rash and elevated BUN were reported.
Implications:
- Cefoperazone (CPZ) presents a promising therapeutic option for bacterial infections, particularly those caused by resistant strains.
- Its broad-spectrum activity and favorable pharmacokinetic profile support its clinical utility.
- Further research may explore its role in treating severe infections and its comparative effectiveness against other advanced cephalosporins.